Christopher Darr

7PUBLICATIONS
96CO-AUTHORS
Predictive and prognostic markersCell physiologyQuery processing and optimisationMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Aug 26, 2026
Sexual function after prostate cancer surgery or radiotherapy in an international registry.

|Sep 06, 2024
Establishing Medical Intelligence-Leveraging Fast Healthcare Interoperability Resources to Improve Clinical Management: Retrospective Cohort and Clinical Implementation Study.

Alexander Brehmer, Christopher Martin Sauer, Jayson Salazar Rodríguez

|Apr 24, 2024
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz

|Dec 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.

Niklas Klümper, Damian J Ralser, Jörg Ellinger

|Oct 12, 2022
Immune-Checkpoint-Inhibitor Therapy-Principles and Relevance of Biomarkers for Pathologists and Oncologists.

Christopher Darr, Thomas Hilser, Claudia Kesch

Pageof 2

Frequent Collaborators

3 joint publications

Marieta Toma

3 joint publications

Katrin Schlack

3 joint publications

Oliver Hahn

3 joint publications

Viktor Grünwald